Nymox Pharm Corp (NYMXF)

$0.07 -0.02 (-22.22%)
Market Cap 8.42M
Revenue (ttm) 0.00
Net Income (ttm) -8.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 25,000
Avg Vol 15,906
Day's Range N/A - N/A
Shares Out 93.54M
Stochastic %K 42%
Beta 10.18
Analysts Strong Buy
Price Target N/A

Company Profile

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert for determining smoking status; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment o...

Industry: Biotechnology
Sector: Healthcare
Phone: (800) 936-9669
Fax: (514) 332-2227
Website: nymox.com
Address:
Bay & Deveaux Streets, 2nd Floor, Nassau, Bahamas
svseeker3000
svseeker3000 Jun. 21 at 3:35 PM
$NYMXF https://www.pacermonitor.com/public/case/57782493/Randall_J_Lanham_v_Computershare_Limited_et_al
0 · Reply
svseeker3000
svseeker3000 Jun. 21 at 3:34 PM
$NYMXF
0 · Reply
Blocktatch
Blocktatch Jun. 14 at 8:08 PM
$NYMXF is there any hope of seeing you listed again?
1 · Reply
svseeker3000
svseeker3000 Jun. 11 at 3:25 PM
$NYMXF https://www.pacermonitor.com/public/case/57782493/Randall_J_Lanham_v_Computershare_Limited_et_al
0 · Reply
usa2018
usa2018 Jun. 11 at 2:32 PM
$NYMXF 4. A note from the case by the Servers of Legal Docs, Dr A’s doorman states he has vacated his Monaco rental apartment, likely heading to Budapest to meet up with a potential new wife from Romania. Strange! 5. At least he put a 6-K out acknowledging he has been sued for tens of millions of dollars by the Restore Group individuals. The big difference is the cases filed against him by the Restore group are real and therefore Dr A will have to answer to.
0 · Reply
usa2018
usa2018 Jun. 11 at 2:30 PM
$NYMXF I’ve been doing some research and here is the latest, it will take 2 posts: 1. News flash and I bet nobody knew this. Nymox voluntarily dismisses lawsuit against Restore group in California. It’s just like he did in Delaware versus Ascella, the company that was going to save the Shareholders. Are the dismissals due to no damages as well as having no money to proceed? 2. Dr A did not file 6-K regarding California dismissal as he should have, but they did file a 6-K on the Delaware case he voluntarily dismissed. Why one and not the other, hiding something from Shareholders? 3. The California voluntary dismissal was not mentioned in the hilariously misleading 20-F that was recently filed, it should have been per SEC rules but when has Dr A followed SEC rules?
0 · Reply
usa2018
usa2018 Jun. 9 at 1:01 PM
$NYMXF There is no backlog with the UK’s drug approval process and most approvals are issued around 200 days. Nymox’s 8th application for approval was accepted by the UK about 29 months ago. That’s about 870 days and not a word about it from Dr A. That’s enough time for 4 drug anpprovals and here we are with zero info. Who thinks there is an approval coming from the UK and more importantly why will this one be different from the 7 prior rejections.
2 · Reply
usa2018
usa2018 Jun. 3 at 7:43 PM
$NYMXF Dr A finally got some year end financials submitted
1 · Reply
giannobes14
giannobes14 May. 29 at 5:17 PM
$NYMXF full transparency I have added a few times over the past few weeks. rationale is a few hundred dollars at this stage is worth the risk even if it goes to $0. The new filing at least lets me know they are still there. still feel it could go either way, I have no idea tbh.
2 · Reply
svseeker3000
svseeker3000 May. 27 at 1:20 PM
$NYMXF https://www.sec.gov/Archives/edgar/data/1018735/000164033425000923/nymox_6k.htm
0 · Reply
Latest News on NYMXF
No data available.
svseeker3000
svseeker3000 Jun. 21 at 3:35 PM
$NYMXF https://www.pacermonitor.com/public/case/57782493/Randall_J_Lanham_v_Computershare_Limited_et_al
0 · Reply
svseeker3000
svseeker3000 Jun. 21 at 3:34 PM
$NYMXF
0 · Reply
Blocktatch
Blocktatch Jun. 14 at 8:08 PM
$NYMXF is there any hope of seeing you listed again?
1 · Reply
svseeker3000
svseeker3000 Jun. 11 at 3:25 PM
$NYMXF https://www.pacermonitor.com/public/case/57782493/Randall_J_Lanham_v_Computershare_Limited_et_al
0 · Reply
usa2018
usa2018 Jun. 11 at 2:32 PM
$NYMXF 4. A note from the case by the Servers of Legal Docs, Dr A’s doorman states he has vacated his Monaco rental apartment, likely heading to Budapest to meet up with a potential new wife from Romania. Strange! 5. At least he put a 6-K out acknowledging he has been sued for tens of millions of dollars by the Restore Group individuals. The big difference is the cases filed against him by the Restore group are real and therefore Dr A will have to answer to.
0 · Reply
usa2018
usa2018 Jun. 11 at 2:30 PM
$NYMXF I’ve been doing some research and here is the latest, it will take 2 posts: 1. News flash and I bet nobody knew this. Nymox voluntarily dismisses lawsuit against Restore group in California. It’s just like he did in Delaware versus Ascella, the company that was going to save the Shareholders. Are the dismissals due to no damages as well as having no money to proceed? 2. Dr A did not file 6-K regarding California dismissal as he should have, but they did file a 6-K on the Delaware case he voluntarily dismissed. Why one and not the other, hiding something from Shareholders? 3. The California voluntary dismissal was not mentioned in the hilariously misleading 20-F that was recently filed, it should have been per SEC rules but when has Dr A followed SEC rules?
0 · Reply
usa2018
usa2018 Jun. 9 at 1:01 PM
$NYMXF There is no backlog with the UK’s drug approval process and most approvals are issued around 200 days. Nymox’s 8th application for approval was accepted by the UK about 29 months ago. That’s about 870 days and not a word about it from Dr A. That’s enough time for 4 drug anpprovals and here we are with zero info. Who thinks there is an approval coming from the UK and more importantly why will this one be different from the 7 prior rejections.
2 · Reply
usa2018
usa2018 Jun. 3 at 7:43 PM
$NYMXF Dr A finally got some year end financials submitted
1 · Reply
giannobes14
giannobes14 May. 29 at 5:17 PM
$NYMXF full transparency I have added a few times over the past few weeks. rationale is a few hundred dollars at this stage is worth the risk even if it goes to $0. The new filing at least lets me know they are still there. still feel it could go either way, I have no idea tbh.
2 · Reply
svseeker3000
svseeker3000 May. 27 at 1:20 PM
$NYMXF https://www.sec.gov/Archives/edgar/data/1018735/000164033425000923/nymox_6k.htm
0 · Reply
usa2018
usa2018 May. 25 at 10:01 PM
$NYMXF Dr A is missing no one can seem to find him. Its time to put his face on milk cartons, that should do it.
0 · Reply
Passeraser
Passeraser May. 25 at 4:30 PM
$NYMXF Sometimes things are not how they seem !!!
1 · Reply
ArtinRIUSA
ArtinRIUSA May. 24 at 12:46 AM
$NYMXF https://www.youtube.com/watch?v=xknQMdp6QRM
0 · Reply
giannobes14
giannobes14 May. 23 at 8:49 PM
$NYMXF them dropping the lawsuit, going MIA again, and lawsuits mounting against them now smells like the end to me. Not that anything was really going on here for a while but they couldnt put up a win in normal times cant imagine no cash, MIA CEO, multiple lawsuits, etc. and they pull it out
2 · Reply
usa2018
usa2018 May. 22 at 6:28 PM
$NYMXF i received a private message regarding the extension. Here is the message: “The 20-F filing due date is April 30, 2025 - you can request an extension one day later, which is May 1, 2025; that extension gives you 15 days extra time to file. After May 15, 2025 your annual filing is late.” The danger is that at any moment the SEC can prevent trading once again just like Canada has. So either get out at 6 cents and have dinner or run the risk of not being able to sell at all. That Dr A is a strange one.
3 · Reply
svseeker3000
svseeker3000 May. 22 at 1:54 PM
$NYMXF https://www.pacermonitor.com/public/case/57830097/Chris_Riley_v_Computershare_Limited_et_al
0 · Reply
usa2018
usa2018 May. 21 at 5:44 PM
$NYMXF I’m sure Dr A would never lie or mislead his loyal Shareholders on the extension to the annual financials, but does anyone know when the 15 day extension starts. I do hope he has the 2021, 2022, 2023 and the 2024 Annual Meetings at the same time so the loyal Shareholders don’t have to keep flying to the Bahamas to attend them. I’m told Dr A is honest and ethical and that’s why we did not need the Restore Group or Ascella. I’m sure he will schedule the annual meeting so as to not inconvenience Shareholders. Dr A is quite a guy, not many like him. I’m sure that in just a few days he will update us on the UK and all the other applications. Why do all these Regulators have so much trouble approving Dr A’s applications? Someone should look into it.
0 · Reply
giannobes14
giannobes14 May. 20 at 9:36 PM
$NYMXF Can't imagine anything happens soon here. I think every initiative is at a standstill and now the company / Averback is getting sued? Scratching my head on UK and plans for the Ascella Health ordeal. Don't understand how they are staying afloat at this point. The lawsuits allegations that management was selling shares during this downturn would be wild if true.
0 · Reply
Notanymore
Notanymore May. 14 at 12:32 AM
$NYMXF Amy chance we will see 0.12 before we are all dead? That’s cents, not bucks
1 · Reply
longtermgonedaily
longtermgonedaily May. 13 at 5:00 AM
$NYMXF We need this to happen…
1 · Reply
svseeker3000
svseeker3000 May. 12 at 11:04 PM
$NYMXF https://www.pacermonitor.com/public/case/57782493/Randall_J_Lanham_v_Computershare_Limited_et_al
0 · Reply
usa2018
usa2018 May. 12 at 6:16 PM
$NYMXF The new Auditors of Nymox must have their heads spinning. First, they probably must comply with the PCAOB Requirements and that is a huge challenge the way Nymox is operates. Is a 15-day extension on filing the Annual Financials going to make everything ok and hide the UK answer? Nymox has no money, product or leadership and they play a game of delaying communication and when they must communicate its dishonest. Europe application has been gone for 7 years, the FDA for 3 years, Denmark for 2 years and it’s been 1 year since the UK has provided their concerns and questions to DR A so all this should be highlighted in the financials along with the Auditors expectation of the UK final answer. Plus, there are new Lawsuits against DR A and Nymox which will have to be explained which may expose Dr A’s double dipping of Salary, Bonuses and Stock Awards. These new Auditors have a duty to protect the Shareholders. Exposing the truth of Dr A will end this charade.
1 · Reply